Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
S&S Healthcare Holding's Days Sales Outstanding for the
three
months ended in Dec. 2025 was 62.06.
S&S Healthcare Holding's Days Inventory for the
three
months ended in Dec. 2025 was 117.7.
S&S Healthcare Holding's Days Payable for the
three
months ended in Dec. 2025 was 29.12.
Therefore, S&S Healthcare Holding's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2025 was 150.64.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
S&S Healthcare Holding Cash Conversion Cycle Related Terms
S&S Healthcare Holding Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for S&S Healthcare Holding's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4198 vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, S&S Healthcare Holding's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
S&S Healthcare Holding Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, S&S Healthcare Holding's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where S&S Healthcare Holding's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
S&S Healthcare Holding's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
S&S Healthcare Holding (ROCO:4198) has a Cash Conversion Cycle of 150.64 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on S&S Healthcare Holding and its competitors.
Is S&S Healthcare Holding's Cash Conversion Cycle too high?
S&S Healthcare Holding's current Cash Conversion Cycle is 150.64. The Medical Devices & Instruments industry median Cash Conversion Cycle is 157.71. S&S Healthcare Holding's value of 150.64 is 4.5% below this industry median. Overall, S&S Healthcare Holding has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does S&S Healthcare Holding's Cash Conversion Cycle compare to ABT and SYK?
S&S Healthcare Holding's Cash Conversion Cycle of 150.64 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 157.71. S&S Healthcare Holding's value of 150.64 is 4.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 157.71, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. S&S Healthcare Holding's current Cash Conversion Cycle of 150.64 is 4.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on S&S Healthcare Holding and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 157.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. S&S Healthcare Holding's current Cash Conversion Cycle is 150.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is S&S Healthcare Holding stock overvalued right now?
Based on GuruFocus' analysis, S&S Healthcare Holding (ROCO:4198) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$23.68, compared to a current price of NT$38.05 — trading 60.7% above its estimated fair value. The current Cash Conversion Cycle is 150.64 and 4.5% below the Medical Devices & Instruments industry median of 157.71. S&S Healthcare Holding's overall GF Score™ is 54/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For S&S Healthcare Holding (ROCO:4198), the current Cash Conversion Cycle is 150.64 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is S&S Healthcare Holding (ROCO:4198) Overvalued in 2026?
Based on GuruFocus' analysis, S&S Healthcare Holding stock appears to be overvalued.
The current stock price of NT$38.05 is trading 60.7% above its estimated GF Value™ of NT$23.68.
GuruFocus considers S&S Healthcare Holding to be Significantly Overvalued.
Key valuation signals for ROCO:4198:
Cash Conversion Cycle: 150.64
GF Value™: NT$23.68 vs. price of NT$38.05 (60.7% above fair value)
Industry Position: 4.5% below the Medical Devices & Instruments median
No single metric tells the full story. See the ROCO:4198 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
S&S Healthcare Holding Ltd, formerly Swissray Global Healthcare Holding Ltd is involved in providing DR systems designed for any application in general radiography. The product divisions of the company cover Swissray DDR systems, Novadaq, and EZ2GO. The main business projects of the company and its subsidiaries are the research and development, manufacturing, sales, and maintenance services of high-end medical equipment and the manufacturing and sales of basic medical equipment.
54GF Score
Get the complete analysis for ROCO:4198
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4198 has been successfully added to your 
